These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17653499)

  • 41. Mild cognitive impairment clinical trials.
    Petersen RC
    Nat Rev Drug Discov; 2003 Aug; 2(8):646-53. PubMed ID: 12904814
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preference-based quality of life in patients with Alzheimer's disease.
    Karlawish JH; Zbrozek A; Kinosian B; Gregory A; Ferguson A; Glick HA
    Alzheimers Dement; 2008 May; 4(3):193-202. PubMed ID: 18631968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Caregivers' assessments of preference-based quality of life in Alzheimer's disease.
    Karlawish JH; Zbrozek A; Kinosian B; Gregory A; Ferguson A; Low DV; Glick HA
    Alzheimers Dement; 2008 May; 4(3):203-11. PubMed ID: 18631969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease.
    Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977
    [No Abstract]   [Full Text] [Related]  

  • 46. [Reality of pharmacotherapy in nursing home patients with dementia. Results of a new field study of 23 nursing homes].
    Hallauer J
    Krankenpfl J; 2005; 43(7-10):206. PubMed ID: 16515277
    [No Abstract]   [Full Text] [Related]  

  • 47. [Symptomatic therapy of Alzheimer dementia].
    Förstl H
    Wien Med Wochenschr; 2002; 152(3-4):77-80. PubMed ID: 11925776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing outcomes in Alzheimer disease.
    Schneider LS
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S8-18. PubMed ID: 11669509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Possibilities and limits of therapy of cognition disorders in the elderly].
    Hoyer S
    Z Gerontol Geriatr; 1995; 28(6):457-62. PubMed ID: 8581765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The characteristics of Alzheimer's Disease Units in relation to neuropsychological tests].
    Sorrentino GC; Caffari B; Vanacore N; Maggini M; Raschetti R
    Ann Ist Super Sanita; 2005; 41(1):63-8. PubMed ID: 16037652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cardiac effects of cholinesterase inhibitors: a reason for restraint?].
    Salarbaks AM; Boomkamp-Snoeren CM; van Puijenbroek E; Jansen PA; van Marum RJ
    Tijdschr Gerontol Geriatr; 2009 Apr; 40(2):79-84. PubMed ID: 19472574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland].
    Monsch AU; Büla C; Hermelink M; Kressig RW; Martensson B; Mosimann U; Müri R; Vögeli S; von Gunten A;
    Praxis (Bern 1994); 2012 Sep; 101(19):1239-49. PubMed ID: 22991148
    [No Abstract]   [Full Text] [Related]  

  • 53. length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Levy R
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():33. PubMed ID: 9305513
    [No Abstract]   [Full Text] [Related]  

  • 54. [Alzheimer drugs for mild cognitive impairment].
    Fellgiebel A
    Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Donepezil in the treatment of patients with Alzheimer's disease.
    Tsuno N
    Expert Rev Neurother; 2009 May; 9(5):591-8. PubMed ID: 19402770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The progression of behavior in dementia: an in-office guide for clinicians.
    Kilik LA; Hopkins RW; Day D; Prince CR; Prince PN; Rows C
    Am J Alzheimers Dis Other Demen; 2008; 23(3):242-9. PubMed ID: 18272657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales.
    Demers L; Oremus M; Perrault A; Champoux N; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):170-80. PubMed ID: 11128057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
    Meguro M; Kasai M; Akanuma K; Ishii H; Yamaguchi S; Meguro K
    Age Ageing; 2008 Jul; 37(4):469-73. PubMed ID: 18515851
    [No Abstract]   [Full Text] [Related]  

  • 60. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.